These collective findings highlight P. goldsteinii as a novel therapeutic candidate for COPD, offering dual modulation of gut-lung axis dysfunction and TLR4-driven inflammation (Lai et al., 2022b). Here, TLR4 is linked to chronic obstructive pulmonary disease.